JP7881608B2 - タファミジスの固体形態及びその製造方法 - Google Patents

タファミジスの固体形態及びその製造方法

Info

Publication number
JP7881608B2
JP7881608B2 JP2023565586A JP2023565586A JP7881608B2 JP 7881608 B2 JP7881608 B2 JP 7881608B2 JP 2023565586 A JP2023565586 A JP 2023565586A JP 2023565586 A JP2023565586 A JP 2023565586A JP 7881608 B2 JP7881608 B2 JP 7881608B2
Authority
JP
Japan
Prior art keywords
benzoxazole
dichlorophenyl
carboxylic acid
tafamidis
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023565586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515770A (ja
JP2024515770A5 (cg-RX-API-DMAC10.html
Inventor
バッレーカ,ジュゼッペ
カーコーネ,ルカ
パラヴィディーノ,ピエロ
ペンゴ,ダニエル
ザンピエーリ,マッシモ
フアン,リミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quimica Sintetica SA
Original Assignee
Quimica Sintetica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimica Sintetica SA filed Critical Quimica Sintetica SA
Publication of JP2024515770A publication Critical patent/JP2024515770A/ja
Publication of JP2024515770A5 publication Critical patent/JP2024515770A5/ja
Application granted granted Critical
Publication of JP7881608B2 publication Critical patent/JP7881608B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
JP2023565586A 2021-04-26 2022-04-22 タファミジスの固体形態及びその製造方法 Active JP7881608B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382362.8 2021-04-26
EP21382362.8A EP4083027A1 (en) 2021-04-26 2021-04-26 A solid state form of tafamidis and a process for its preparation
PCT/EP2022/060716 WO2022229026A1 (en) 2021-04-26 2022-04-22 A solid state form of tafamidis and a process for its preparation

Publications (3)

Publication Number Publication Date
JP2024515770A JP2024515770A (ja) 2024-04-10
JP2024515770A5 JP2024515770A5 (cg-RX-API-DMAC10.html) 2025-03-10
JP7881608B2 true JP7881608B2 (ja) 2026-06-29

Family

ID=75746555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565586A Active JP7881608B2 (ja) 2021-04-26 2022-04-22 タファミジスの固体形態及びその製造方法

Country Status (8)

Country Link
US (1) US20240208915A1 (cg-RX-API-DMAC10.html)
EP (2) EP4083027A1 (cg-RX-API-DMAC10.html)
JP (1) JP7881608B2 (cg-RX-API-DMAC10.html)
CN (1) CN117255781A (cg-RX-API-DMAC10.html)
BR (1) BR112023022116A2 (cg-RX-API-DMAC10.html)
CA (1) CA3216325A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023012460A (cg-RX-API-DMAC10.html)
WO (1) WO2022229026A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023091534A1 (en) * 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
WO2026159144A1 (en) 2025-01-22 2026-07-30 Inke, S.A. Solid forms of tafamidis methyl ethyl ketone solvate and processes for their manufacture

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016065042A (ja) 2014-09-08 2016-04-28 ファイザー・インク 6−カルボキシ−2−(3,5−ジクロロフェニル)−ベンゾオキサゾールの結晶性固体形態
WO2020232325A1 (en) 2019-05-16 2020-11-19 Teva Pharmaceuticals International Gmbh Solid state forms of tafamidis and salts thereof
WO2021001858A1 (en) 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
KR20130079353A (ko) * 2010-04-21 2013-07-10 키에시 파르마슈티시 엣스. 피. 에이. 트랜스티레틴 아밀로이드증 치료용 1-(2-플루오로비페닐-4-일)-알킬 카복실산 유도체
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
WO2021019448A1 (en) 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
WO2022084790A1 (en) * 2020-10-19 2022-04-28 Glenmark Life Sciences Limited Process for preparation of tafamidis and salts thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016065042A (ja) 2014-09-08 2016-04-28 ファイザー・インク 6−カルボキシ−2−(3,5−ジクロロフェニル)−ベンゾオキサゾールの結晶性固体形態
WO2020232325A1 (en) 2019-05-16 2020-11-19 Teva Pharmaceuticals International Gmbh Solid state forms of tafamidis and salts thereof
WO2021001858A1 (en) 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
小嶌隆史,医薬品開発における結晶性選択の効率化を目指して,薬剤学,2008年09月01日,Vol.68, No.5,pp.344-349
浅原 照三,溶剤ハンドブック,株式会社 講談社,1985年,pp. 47-51
社団法人日本化学会,化学便覧応用化学編第6版,第4章化学合成技術,丸善株式会社,2003年01月30日,第178頁
芦澤一英,医薬品の多形現象と晶析の科学,丸善プラネット株式会社,2002年,pp.56-102, 304-317
高田則幸,創薬段階における原薬Formスクリーニングと選択,PHARM STAGE,Vol.6, No.10,2007年01月15日,p.20-25

Also Published As

Publication number Publication date
CN117255781A (zh) 2023-12-19
BR112023022116A2 (pt) 2024-01-09
JP2024515770A (ja) 2024-04-10
EP4330237A1 (en) 2024-03-06
EP4083027A1 (en) 2022-11-02
MX2023012460A (es) 2023-12-14
CA3216325A1 (en) 2022-11-03
WO2022229026A1 (en) 2022-11-03
US20240208915A1 (en) 2024-06-27

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260617

R150 Certificate of patent or registration of utility model

Ref document number: 7881608

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150